The U.S. Food and Drug Administration (FDA) has granted traditional approval to ELEVIDYS for ambulatory Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) patients and accelerated approval for non-ambulatory patients.
ELEVIDYS is now indicated for individuals with DMD who are at least 4 years old and have a confirmed DMD gene mutation. The label expansion includes both ambulatory and non-ambulatory patients.
• Traditional approval for ambulatory patients confirms the functional benefits of ELEVIDYS.
• Accelerated approval for non-ambulatory patients is contingent upon continued verification of clinical benefit in a confirmatory trial.
ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.
Sarepta Therapeutics, the manufacturer of ELEVIDYS, hailed the FDA approval as a significant milestone and a victory for gene therapy. The company praised the scientific evidence and the commitment of researchers, clinicians, and patient families.
Sarepta is conducting a postmarketing study, ENVISION, to confirm the clinical benefit of ELEVIDYS in non-ambulatory patients.
Sarepta is collaborating with Roche to develop innovative therapies for DMD, aiming to enhance muscle function and improve the quality of life for those affected.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
